Evidence map›Paper›PMID 31787897›Full record

ArticleFrontiers in pharmacology2019

Involvement of Phosphatase and Tensin Homolog in Cyclin-Dependent Kinase 4/6 Inhibitor-Induced Blockade of Glioblastoma.

Songlin Liu, Dun Yuan, Yifeng Li, Qi Qi, Bingzhong Guo, Shun Yang, Jilin Zhou, Lu Xu, Tiange Chen, Chenxing Yang and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Songlin LiuDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
Dun YuanDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
Yifeng LiDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
Qi QiDepartment of Pharmacology, Clinical Translational Center for Targeted Drug, School of Medicine, Jinan University, Guangzhou, China.
Bingzhong GuoDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
Shun YangDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
Jilin ZhouDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
Lu XuDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
Tiange ChenDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
Chenxing YangDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
Junyu LiuDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
Buyan LiDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
Li YaoDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
Weixi JiangDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
Xiangya Hospital Central South University · CNCentral South University · CNJinan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dysregulation of retinoblastoma (Rb) signaling pathway have been established as a requirement for glioblastoma (GBM) initiation and progression, which suggests that blockade of CDK4/6-Rb signaling axis for GBM treatment. Palbociclib, a selective inhibitor of the cyclin-dependent kinases CDK4/6, has been applied for breast cancer treatment. However, its efficacy against glioblastoma has not been well clarified. Here, effects of CDK4/6 inhibitors on various kinds of GBM cell lines are investigated and the functional mechanisms are identified. Data showed that cells with diverse PTEN status respond to palbociclib differently. Gain-of-function and loss-of-function studies indicated that PTEN enhanced the sensitivity of GBM cells to palbociclib

Indexed as

CDK4/6 inhibitorglioblastomapalbociclibPTENsensitivity

Identifiers

PMID31787897
PMCPMC6854038
OpenAlexW2985568914

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.